A $58 million deal to bail out the failed Australian arm of Ellume, a once soaring biotechnology star supplying COVID-19 tests, has fallen over.
The financial lifeline had been proposed by a Gold Coast firm with controversial links to testing, but Ellumes administrators said it failed to come up with the required funds.
It means Ellumes Australian arm the head of the group has tumbled into liquidation, costing at least 40 jobs and imperilling almost $200 million in creditor claims. The Australian business owned the shares in its North American subsidiary, which is not in administration and has a contract with the US Depart…
Read the full article at: https://www.afr.com/companies/healthcare-and-fitness/ellume-s-58m-bailout-fails-as-rival-misses-deadline-20230615-p5dgu3